Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Cervical Cancer
How does your approach to the primary treatment of glassy cell carcinoma of the cervix differ from the primary treatment of squamous cell or adenocarcinoma of the cervix?
Answer from: at Community Practice
No difference.
Sign in or Register to read more
13922
Related Questions
How long would you continue Bevacizumab and Pembrolizumab after completing 6 cycles of quad therapy (Carbo/ Taxol/ Bev/ Pembro) in a patient with metastatic cervical carcinoma with no evidence of disease (CR) on imaging?
Do the results of the ConCerv and SHAPE trials alter how you might counsel a patient incidentally found to have ≤IB1 after simple hysterectomy?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
How would you manage a recurrent cervical cancer previously treated with vaginal cuff brachytherapy and has had a complete response to chemo-immunotherapy?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
Now that the INTERLACE trial is published, do you plan to do induction chemotherapy prior to chemoRT or chemoRT with immunotherapy (per KEYNOTE-A18) for locally advanced cervical cancer?
In the context of the ConCerv and SHAPE trials, how would you approach a patient with endometrioid adenocarcinoma within an excised 1.2 cm cervical polyp (negative for LVSI) who has no suspicious lymph nodes on CT scan?
How would you manage a young, healthy patient s/p open radical hysterectomy/bilateral salpingectomy/ovarian transposition/bilateral SLND with now stage IB3 HPV-dependent adenosquamous cervical carcinoma?